upgrad buy
upgrad buy
upgrad johnson johnson buy neutral rais po
upgrad due belief current
unpreced environ defens name continu outperform
long histori outperform difficult time jnj strong result
dividend rais suggest deliv solid result especi rel
challeng time well also think risk around pharma price
lower due view decis distribut vaccin
prove success non-for-profit basi master stroke note
outperform meaning last two recess
outperform respect
think gap pharma valuat med-tech valuat could narrow
significantli given med-tech continu trade almost ten year rel high
versu pharma despit materi larger covid-rel cut ep med-tech
benefit view valuat gap narrow trade close
valuat discount med-tech one year forward earn trade
discount well year averag new
po assum trade premium slightli
see two key risk call first jnj guidanc call v-shape
recoveri seem optimist view name ep uncertainti today
risk number probabl less second litig risk talc
opioid remain potenti concern concern outweigh strength
jnj rel posit current environ view
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
johnson johnson lead global health care
compani develop manufactur market
diversifi portfolio product
pharmaceut medic devic consum
rate buy given stock trade
discount seem rel
mispric given strong rel outlook
challeng time abl
deliv strong result pressur
background call
uncertain environ favor defens name paradox bullish call
today subscrib state view recoveri v-
shape would prefer name lever quick recoveri orthoped name
exampl inde conserv view magnitud pace
recoveri elect procedur play larg role bullish view
next month think pharma may outperform med-tech think
outperform market last two recess see tabl
defens pure play med-tech name reason valuat becton
dickinson po baxter po larg cap hill-rom po
mid cap continu recommend name well
po po take big hit number near term
sell kind technolog project like return close
normal level later reason valu
rel call seem easier absolut call highli confid
like trade much higher premium market next
jnj perform prior recess
chart previous outperform econom downturn
chart ntm price-to-earnings rel
ntm price-to-earnings rel
averag ntm price-to-earnings rel
chart ntm price-to-earnings rel larg cap med-tech
ntm price-to-earnings rel larg cap med-tech
averag ntm price-to-earnings rel larg cap med-tech
tabl bofa annual revenu ep project johnson johnson
bofa total johnson johnson sale
opioid talc litig updat
confirm agreement principl octob
name lawsuit brought certain state local
govern relat market opioid
agreement principl intend provid certainti
involv parti critic assist famili commun
need admiss liabil wrong-do would resolv
lawsuit file futur claim state citi counti
continu work negoti committe state
attorney gener ag final agreement principl
remain optimist predict opt
state ag process new york state trial schedul
begin march delay indefinit march due
impact time resumpt trial still tbd
state slate begin trial later year includ
mississippi louisiana ohio
multi-district litig mdl process involv nearli
municip minim updat chang
last month
next mileston mdl process determin
negoti class aggreg plaintiff togeth legal
framework use previous decis like
come
ultim focu like fall state ag process
also lawsuit file individu plaintiff behalf
children suffer neonat abstin syndrom hospit
payor note confid market
promot practic provid medic appropri
respons
await daubert rule judg wolfson feder court
believ could hear rule time remain optimist
regard outcom time rule judg discret
price object base earn multipl ep
estim multipl peer think justifi given low doubl
digit ep growth profil long term potenti drive upsid ep
balanc sheet activ upside/downsid risk po margin expand
revenu grow faster/slow rate expect strateg activ
view posit neg
becton dickinson compani
price object base ep estim multipl
line larg cap peer think warrant given long term growth
profil mid-singl digit
downsid risk po increas competit slower growth emerg
market price eros lower healthcar util trend soft uptak new
diagnost product slower growth hospit capit spend
price object deriv cash ep estim
premium larg cap med-tech comp group justifi believ given view
acceler earn growth outlook base opportun drive
averag top line growth meaning oper leverag
downsid risk price object de competit dynam
increment price pressur declin reimburs
po base ep estim line larg cap
med-tech think line multipl justifi given long term doubl digit ep
growth profil
upsid risk po better capit equip spend cycl better-than-
expect margin improv accret strateg activ downsid risk po
slowdown hospit capit spend inabl execut current
price object base previous ep
estim approxim line larg cap med devic peer believ
valuat justifi given resili busi challeng econom
downsid risk po includ longer expect pressur medic
devic busi due continu deferr elect medic
procur on-going litig continu longer expect and/or result
price object base trade ep
line peer think valuat warrant revenu growth
acceler post calendar driven new product launch innov
includ micraav new robot
upsid risk price object greater-than-expect revenu growth new
product robot develop market share gain competit product delay
acceler end-market growth downsid risk price object
competit share loss and/or price pressur
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
